]>
IRCT20200317046797N1 IRCT 2020-04-03 Tabriz University of Medical Sciences Effect of Camostate mesylate on the outcome of Coronavirus (COVID-19)-induced pneumonia ComCov Effect of Camostate mesylate on clinical improvement and outcome of Coronavirus (COVID-19)-induced pneumonia 2020-04-08 anticipated 40 Complete https://irct.ir/trial/46573 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Health service research, Randomization description: Simple randomization sequence will be generated with a computer from 1 to 40. The computer will divide the digits between the two groups. According to the sequence of admission, the patients will be allocated to the control or the Camostate mesylate groups regarding the sequence of computerized random list. 3 Condition 1: Coronavirus (COVID-19)-induced pneumonia. Condition 2: COVID-19. Intervention 1: Intervention group: Twenty patients with Coronavirus (COVID-19)-induced pneumonia in addition to standard regimen of covid-19, will receive Camostate mesylate tablets for 3 days (200 mg three times daily). Intervention 2: Control group: they will receive standard regimen for COVID-19 patients. No - There is not a plan to make this available Justification or reason for not sharing IPD is Considering the crisis conditions of the Pandemic Corona and the increasing number of patients, our top priorities are the patients management and the search for effective medication (s).
public Dr Khalil Ansarin
Imam Reza Hospital; Golgasht street
Tabriz Iran (Islamic Republic of) 5166616471 +98 41 3335 2898 dr.ansarin@gmail.com Tabriz University of Medical Sciences scientific Mohammad Reza Ardalan
Golgasht street
Tabriz Iran (Islamic Republic of) 5166614766 +98 41 3336 9331 ardalan34@yahoo.com Tabriz University of Medical Sciences Iran (Islamic Republic of) Moderate to severe 2019-nCoV-infected patients Being at the age of 18 to 80 years Patients or authorized family members volunteered to participate in this study and signed informed consent. Both genders pulmonary involvement in CT scan PCR positive 18 years 80 years Both Patient with elevated liver enzymes 3 time the upper limit of normal Patients who are participating in other drug clinical trials Patients with active pulmonary tuberculosis Patients with definite bacterial and fungal infections Pregnant or lactating women Patient with active thrombotic event J12.89 U07.1 Other viral pneumonia COVID-19, virus identified Treatment - Drugs Treatment - Drugs Intervention group: Twenty patients with Coronavirus (COVID-19)-induced pneumonia in addition to standard regimen of covid-19, will receive Camostate mesylate tablets for 3 days (200 mg three times daily). Control group: they will receive standard regimen for COVID-19 patients. Lung symptoms. Timepoint: At baseline (before intervention) and after drug administration. Method of measurement: Lung CT scan. Hospitalization period. Timepoint: At baseline and discharge time. Method of measurement: Counting the day. Mortality rate. Timepoint: At baseline and discharge time. Method of measurement: Observation. Need for intubation. Timepoint: At baseline and discharge time. Method of measurement: Observation. Tabriz University of Medical Sciences Approved 2020-03-17 Ethics committee of Tabriz University of Medical Sciences Tabriz University of Medical Sciences Tabriz East Azarbaijan Iran (Islamic Republic of)